Literature DB >> 20135076

Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics.

Richard C Becker1, Thomas Povsic, Mauricio G Cohen, Christopher P Rusconi, Bruce Sullenger.   

Abstract

Antithrombotic therapy for the acute management of thrombotic disorders has been stimulated and guided actively by our current understanding of platelet biology, coagulation proteases, and vascular science. A translatable platform for coagulation, based soundly on biochemistry, enzymology and cellular events on platelets and tissue factor-baring cells, introduces fundamental constructs, mechanistic clarity, and an unparalleled opportunity for accelerating the development and clinical investigation of both disease- and patient-specific therapies. In the current review, we build upon and expand substantially our observations surrounding nucleic acids as antithrombotic agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20135076     DOI: 10.1160/TH09-10-0716

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

Review 1.  New anticoagulants in ischemic heart disease.

Authors:  Lawrence Rajan; David J Moliterno
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

Review 2.  Modulation of the Coagulation Cascade Using Aptamers.

Authors:  Rebecca S Woodruff; Bruce A Sullenger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-08-27       Impact factor: 8.311

3.  Thermodynamics of ligand binding to a heterogeneous RNA population in the malachite green aptamer.

Authors:  Joshua E Sokoloski; Sarah E Dombrowski; Philip C Bevilacqua
Journal:  Biochemistry       Date:  2011-12-16       Impact factor: 3.162

4.  Aptamer that binds to the gD protein of herpes simplex virus 1 and efficiently inhibits viral entry.

Authors:  Subash C B Gopinath; Kyoko Hayashi; Penmetcha K R Kumar
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

5.  Several structural motifs cooperate in determining the highly effective anti-thrombin activity of NU172 aptamer.

Authors:  Romualdo Troisi; Valeria Napolitano; Vera Spiridonova; Irene Russo Krauss; Filomena Sica
Journal:  Nucleic Acids Res       Date:  2018-12-14       Impact factor: 16.971

Review 6.  Translation and Clinical Development of Antithrombotic Aptamers.

Authors:  Shahid M Nimjee; Thomas J Povsic; Bruce A Sullenger; Richard C Becker
Journal:  Nucleic Acid Ther       Date:  2016-02-16       Impact factor: 5.486

7.  A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.

Authors:  Thomas J Povsic; John P Vavalle; Laura H Aberle; Jaroslaw D Kasprzak; Mauricio G Cohen; Roxana Mehran; Christoph Bode; Christopher E Buller; Gilles Montalescot; Jan H Cornel; Andrzej Rynkiewicz; Michael E Ring; Uwe Zeymer; Madhu Natarajan; Nicolas Delarche; Steven L Zelenkofske; Richard C Becker; John H Alexander
Journal:  Eur Heart J       Date:  2012-08-02       Impact factor: 29.983

8.  High-resolution structures of two complexes between thrombin and thrombin-binding aptamer shed light on the role of cations in the aptamer inhibitory activity.

Authors:  Irene Russo Krauss; Antonello Merlino; Antonio Randazzo; Ettore Novellino; Lelio Mazzarella; Filomena Sica
Journal:  Nucleic Acids Res       Date:  2012-06-04       Impact factor: 16.971

Review 9.  In vitro and ex vivo selection procedures for identifying potentially therapeutic DNA and RNA molecules.

Authors:  Soledad Marton; José A Reyes-Darias; Francisco J Sánchez-Luque; Cristina Romero-López; Alfredo Berzal-Herranz
Journal:  Molecules       Date:  2010-06-28       Impact factor: 4.411

Review 10.  Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics.

Authors:  Domenica Musumeci; Chiara Platella; Claudia Riccardi; Federica Moccia; Daniela Montesarchio
Journal:  Cancers (Basel)       Date:  2017-12-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.